Express Scripts Chooses AbbVie Hepatitis C Drug Over Gilead: What It Means for Mutual Fund Investors (GILD)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Gilead Sciences, Inc.

News

Express Scripts Chooses AbbVie Hepatitis C Drug Over Gilead: What It Means for Mutual Fund Investors (GILD)

Shauna O'Brien Dec 22, 2014



Inside the News



Turning Point for Biotech?


Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.

This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.

It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.


Mutual Funds to Watch



The Bottom Line


Shares of GILD are up 28% YTD.

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book